Costello Asset Management’s Matinas BioPharma MTNB Stock Holding History

Costello Asset Management’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$122	Hold	200	–	–	﹤0.01%	706
2026 Q1	$100	Hold	200	–	–	﹤0.01%	682
2025 Q4	$117	Hold	200	–	–	﹤0.01%	689
2025 Q3	$378	Hold	200	–	–	﹤0.01%	652
2025 Q2	$178	Hold	200	–	–	﹤0.01%	681
2025 Q1	$104	Buy	+200	New	+$118	﹤0.01%	679

Other funds holding MTNB

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

HIW

Holos Integrated Wealth Kennett Square, Pennsylvania $214M AUM 14.99% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $832M AUM 24.89% 1-Year Est. Return

Costello Asset Management's MTNB Position: Q2 2026 in Review

Costello Asset Management held its Matinas BioPharma (MTNB) position steady in Q2 2026 at 200 shares worth $122. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Costello Asset Management first reported a position in MTNB in Q1 2025 and has held it in 6 quarters since. The position peaked at $378 in Q3 2025. 25 funds tracked by Wall St. Rank hold MTNB as of Q2 2026.

Costello Asset Management held 200 shares of Matinas BioPharma worth $122 as of Q2 2026.
Costello Asset Management left its Matinas BioPharma share count unchanged in Q2 2026.
Matinas BioPharma made up ﹤0.01% of Costello Asset Management's portfolio in Q2 2026, its #706 holding.
Costello Asset Management first reported a position in Matinas BioPharma in Q1 2025 and has held it in 6 quarters since.
Costello Asset Management's Matinas BioPharma position peaked at $378 in Q3 2025.
25 funds tracked by Wall St. Rank held Matinas BioPharma as of Q2 2026.

Based on Costello Asset Management's 13F filing for Q2 2026, filed 28 Jul 2026.